Rituximab-Based Regimen As First-Line Treatment in Chinese Patients with Follicular Lymphoma: Three-Year Safety Data from a Prospective, Observational Study

被引：0
|
作者：
Wu, Jianqiu
Song, Yongping
Su, Liping
Zhang, Mingzhi
Li, Wei
Hu, Yu
Zhang, Xiaohong
Gao, Yuhuan
Niu, Zuoxing
Feng, Ru
Wang, Wei
Peng, Jiewen
Li, Xiaolin
Ouyang, Xuenong
Wu, Changping
Zhang, Weijing
Zeng, Yun
Xiao, Zhen
Liang, Yingmin
Zhuang, Yongzhi
Wang, Jishi
Sun, Zimin
Bai, Hai
Cui, Tongjian
Feng, Jifeng
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5167
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study
    Panizo, Carlos
    Bekadja, Mohamed Amine
    Meddeb, Balkis
    Mendoza, Maria Rigoroso
    Truman, Matt
    Smith, Rodney
    Barate, Claudia
    BLOOD, 2016, 128 (22)
  • [22] Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial
    Kahl, Brad S.
    Burke, John M.
    van der Jagt, Richard
    Chang, Julie
    Wood, Peter
    Hawkins, Tim
    MacDonald, David
    Trotman, Judith
    Simpson, David
    Kolibaba, Kathryn S.
    Issa, Samar
    Hallman, Doreen
    Chen, Ling
    Flinn, Ian W.
    BLOOD, 2017, 130
  • [23] Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab
    Spacek, Martin
    Obrtlikova, Petra
    Hrobkova, Stanislava
    Cmunt, Eduard
    Karban, Josef
    Molinsky, Jan
    Simkovic, Martin
    Mocikova, Heidi
    Mohammadova, Lekaa
    Panovska, Anna
    Novak, Jan
    Trneny, Marek
    Smolej, Lukas
    Doubek, Michael
    LEUKEMIA RESEARCH, 2019, 79 : 17 - 21
  • [24] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [25] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [26] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
  • [27] EFFICACY AND SAFETY OF LOW-INTENSITY ORAL AND INTRAVENOUS FLUDARABINE-CYCLOPHOSPHAMYDE WITH AND WITHOUT RITUXIMAB FOR FIRST-LINE TREATMENT OF FOLLICULAR LYMPHOMA
    Marin-Niebla, A.
    Rios-Herranz, E.
    Falantes Gonzalez, J. E.
    Cerezuela, P.
    Martino Galiana, M. L.
    Parody Ruiz-Berdejo, R.
    Urbano-Ispizua, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 397 - 397
  • [28] Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
    Davies, Andrew
    Merli, Francesco
    Mihaljevic, Biljana
    Mercadal, Santiago
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    Genevray, Magali
    Zharkov, Artem
    Dixon, Mark
    Brewster, Michael
    Barrett, Martin
    MacDonald, David
    LANCET HAEMATOLOGY, 2017, 4 (06): : E272 - E282
  • [29] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
    Sabater, E.
    Rueda, A.
    Salar, A.
    Lopez-Guillermo, A.
    Oyagueez, I.
    Collar, J. M.
    HAEMATOLOGICA, 2014, 99 : 487 - 488
  • [30] FIRST LINE TREATMENT WITH ANTHRACYCLINE-BASED REGIMEN WITH OR WITHOUT RITUXIMAB IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
    Balta, A.
    Panitsas, F.
    Skertsou, M.
    Tzanou, I.
    Gigantes, S.
    Kourti, G.
    Manaka, A.
    Pagoni, M.
    Delibasi, S.
    Apostolidis, J.
    Baltadakis, J.
    Karakasis, D.
    Karmiris, T.
    Bakiri, M.
    Harhalakis, N.
    ANNALS OF ONCOLOGY, 2011, 22 : 220 - 221
12345